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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the benefits and harms of drug-eluting stents versus bare-metal stents in participants with acute coronary syndrome.
B A C K G R O U N D
Description of the condition
Cardiovascular disease, in which ischaemic heart disease is the
largest component, is considered to be the number one cause
of death globally (Lloyd-Jones 2010; Nichols 2014; Rosamond
2008). Ischaemic heart disease is generally divided into acute coro-
nary syndrome and stable ischaemic heart disease (Roffi 2016).
The disease remains prevalent, with more than seven million peo-
ple worldwide expected to develop acute coronary syndrome each
year (White 2008). According to the World Health Organization
(WHO), 7.4 million people died from ischaemic heart disease in
2012, representing 15% of all global deaths, with acute coronary
syndrome accounting for approximately half of the deaths (Turpie
2006; WHO 2015). The in-hospital mortality rates across differ-
ent countries range from 5% to 10% (Gupta 2003). Ischaemic
heart disease remains increasingly prevalent and costly to treat
due to an increase in life expectancy and a decrease in death rates
(Cooper 2000; Schmidt 2012).
Acute coronary syndrome is a collective term for the following:
1. unstable angina pectoris (myocardial ischaemia at rest or
minimal exertion in the absence of cardiomyocyte necrosis (Roffi
2016));
2. non-ST-segment elevation myocardial infarction
(NSTEMI); and
3. ST-segment elevation myocardial infarction (STEMI)
(Amsterdam 2014). Myocardial infarction may be recognised by
clinical features, including electrocardiographic (ECG) findings,
elevated values of biochemical markers (biomarkers) of
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myocardial necrosis, or imaging, or pathology might define it
(Thygesen 2012). The diagnosis of myocardial infarction is
dependent on an elevation of the serum levels of cardiac-specific
troponin I, troponin T, or the myocardial band isoenzyme of
creatine kinase (CK-MB), among others (Roffi 2016). Cardiac
troponin levels will usually be positive within one hour in
patients with myocardial infarction when using high-sensitivity
assays (Roffi 2016). If the initial test is negative, a repeat test is
advisable after three hours to rule out a myocardial infarction,
since in some cases, there is a delay in the elevation of the cardiac
enzymes (Roffi 2016). The changes in the ST-segment reflected
in an ECG provide the basis for the distinction between
NSTEMI and STEMI (Roffi 2016). Compared to NSTEMI and
STEMI, unstable angina pectoris presents without the
characteristic rise in cardiac-specific biomarkers (Roffi 2016).
For research purposes, the causes of myocardial infarction are gen-
erally divided into five main classes (Thygesen 2012).
• Type 1: spontaneous myocardial infarction related to
atherosclerotic plaque rupture, ulceration, fissuring, erosion, or
dissection with resulting intraluminal thrombus in one or more
of the coronary arteries often caused by coronary artery disease.
• Type 2: myocardial infarction secondary to an ischaemic
imbalance, such as coronary artery spasm, coronary embolism,
anaemia, arrhythmias, hypertension, or hypotension.
• Type 3: myocardial infarction with symptoms suggestive of
myocardial ischaemia and resulting in sudden unexpected
cardiac death when biomarker values are unavailable or
unobtainable before death.
• Type 4a: myocardial infarction associated with
percutaneous coronary intervention.
• Type 4b: myocardial infarction associated with stent
thrombosis, as documented by angiography or at autopsy.
• Type 5: myocardial infarction associated with coronary
artery bypass graft.
Major complications associated with myocardial
infarction
• Life-threatening ventricular arrhythmias caused by changes
in the electrophysiologic characteristics of the myocyte,
electrolyte imbalance, continuous ischaemia, and variations in
heart rate, which are all due to obstruction and hence reduced
flow to the myocardium and myocardial necrosis (Brieger 2009;
Stevenson 1989).
• Mechanical complications caused by necrosis of the
myocardium, such as ventricular wall rupture, septum rupture,
and papillary muscle rupture (Brieger 2009; Pohjola-Sintonen
1989; Stevenson 1989).
• Cardiogenic shock caused by failure of the ventricle to
pump an adequate amount of blood leading to systemic
hypotension (Brieger 2009; Stevenson 1989).
• Acute decompensated heart failure caused by impairment in
systolic and diastolic function due to myocardial ischaemia
(Brieger 2009).
• Depression (Thombs 2006).
A narrowing of a coronary vessel causes unstable angina due to
one of five reasons:
1. non-occlusive thrombus on pre-existing plaques;
2. dynamic obstruction, i.e. coronary vasoconstriction;
3. progressive mechanical obstruction, such as restenosis after
percutaneous coronary intervention;
4. inflammation or infection; and
5. secondary unstable angina due to conditions increasing the
oxygen demand, such as hypertension, thyrotoxicosis, and
tachycardia (Braunwald 1998; Roffi 2016). Unstable angina is
associated with lower mortality compared to myocardial
infarction but similar rates of re-hospitalisations; however, it may
have worse quality of life (Dudas 2013; Maddox 2007; Roffi
2016). Patients with unstable angina are also at risk of
cardiogenic shock (Ruiz-Bailén 2008).
Historically, the degree of luminal stenosis and the number of coro-
nary arteries involved (single-vessel disease, double-vessel disease,
or triple-vessel disease) have defined the severity of ischaemic heart
disease (Ringqvist 1983). Researchers have since developed more
comprehensive scorings systems (Gensini 1983; Seizer 1982).
Coronary angiography score and two additional scores, i.e. vas-
cular scoring and stenosis scoring, determine the Gensini score
(Gensini 1983). The results of the coronary angiography deter-
mines the SYNTAX score and takes into account lesion complex-
ity, lesion location, and the number of lesions (Sianos 2005). The
SYNTAXscore II is used to improve the decision-making in choos-
ing between percutaneous coronary intervention (PCI) and coro-
nary artery bypass grafting (CABG) for a long-term, individualised
risk assessment in patients with complex ischaemic heart disease.
The SYNTAX score II combines the anatomical-based SYNTAX
score (Sianos 2005), as well as seven clinical variables (creatinine
clearance, peripheral vascular disease, unprotected left main coro-
nary disease, gender, chronic obstructive pulmonary disease, age,
and left ventricular ejection fraction) (Farooq 2013; Sianos 2005).
A glossary for medical terms is available in Appendix 1.
Description of the intervention
Percutaneous coronary intervention (PCI) is performed by in-
serting an access sheath into a peripheral artery (most often the
femoral artery or the radial artery); a catheter is advanced, under
X-ray screening, through the blood vessels to the aortic root, at the
origin of the coronary arteries. Other tools such as balloons and
stents can then be advanced down the artery, over a guide wire, to
the location of the narrowing or blockage (Cantor 2005; Hamon
2009). Andreas Roland Grüntzig performed the first PCI in 1977
(Grüntzig 1978). PCI has since then evolved to become one of the
cornerstones in the treatment of ischaemic heart disease.
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PCI in patients with acute coronary syndrome can be performed
both as primary and secondary (subacute and elective) PCI (Meyer
1981;Meyer 1982;Meyer 1982a; Meyer 1983). Primary PCI may
be performed in the acute phase of myocardial infarction if pa-
tients present with STEMI. Patients presenting with NSTEMI or
unstable angina pectoris that is characterised as high-risk acute
coronary syndrome may also benefit from undergoing angiogra-
phy and PCI either immediately or as part of an early (within 24
hours) invasive strategy (Hoenig 2010; Roffi 2016). The high-risk
factors include haemodynamic instability, severe left ventricular
dysfunction, recurrent or persistent rest angina, mechanical com-
plications, sustained ventricular tachycardia, and dynamic ST-T
wave electrocardiographic changes (Hoenig 2010).
Secondary PCI includes both subacute PCI and elective PCI. Sub-
acute PCI is generally performed within the first 72 hours af-
ter symptom debut in patients with unstable angina pectoris or
NSTEMI who are not candidates for primary PCI because of be-
ing haemodynamically stable with medical therapy and not at high
risk (Breall 2016; Roffi 2016). Elective PCI is performed in pa-
tients where coronary artery bypass grafting is not indicated, as
well as in patients who are dissatisfied with their quality of life
because of symptoms related to ischaemic heart disease or with
adverse events due to their medical treatment (Levin 2016).
The first PCI was performed by inflating a balloon at the blockage
of the coronary artery to dilate the artery (’balloon angioplasty’)
(Grüntzig 1978; Grüntzig 1979). The healing properties of the
treatment seem to be related to the PCI expanding the outer di-
ameter of the blocked coronary artery and not by decompression
of the arterial plaque (Düber 1986). Balloon angioplasty how-
ever generally did not seem to achieve a long-lasting result, with
restenosis occurring over time (Dangas 2002; Puel 1988). In an
attempt to keep the lumen open for longer, the next development
was a small metallic scaffold called a “stent”. These tubular devices
are expanded over a balloon and press against the walls of the artery
to keep it open (Puel 1988). These first devices were subsequently
termed “bare-metal stents” (after the later introduction of “drug-
eluting stents”) and improved outcomes over balloon angioplasty,
but still had high rates of restenosis over time (Cutlip 2002; Erbel
1998; Fischman 1994; Macaya 1996; Puel 1988; Serruys 1994;
Serruys 1998).
The next stents were drug-eluting stents consisting of three main
components:
1. a metal mesh;
2. an antiproliferative drug (e.g. sirolimus, paclitaxel,
zotarolimus, and everolimus); and
3. a polymer used to coat the metal mesh. An antiproliferative
drug to limit the excessive growth of neointima using cytotoxic
or cytostatic agents, as well as a polymer to control the release of
the antiproliferative drug, supplemented the metal mesh
(Degertekin 2002; Fajadet 2006; Holmes 2004; Lee 2005;
Morice 2002; Moses 2003; Stone 2004; Stone 2004a).
Newer drug-eluting stents have decreased strut thickness and are
meant to have improved flexibility/deliverability, enhanced poly-
mer biocompatibility/drug-eluting profiles, and superior re-en-
dothelialisation kinetics (Serruys 2010; Stone 2010). They typi-
cally use everolimus or zotarolimus as their antiproliferative drug
(Serruys 2010; Stone 2010).
The polymer-coating of the drug-eluting stents has been linked
with adverse events, such as stent thrombosis (Chen 2015). There-
fore, both drug-eluting stents with a biodegradable polymer as well
as polymer-free drug-eluting stents have been developed. Poly-
mer-free drug-eluting stents use the same antiproliferative drugs
(such as paclitaxel or sirolimus) as the polymer drug-eluting stents
(Abizaid 2010; Chen 2015).
In an attempt to further reduce the risk of restenosis, bioresorbable
(also called biodegradable) stents were developed. The principal
components of the bioresorbable stent are the same as the drug-
eluting stents; however, in most cases, a polylactic acid mesh re-
places themetal mesh (Haude 2013; Puricel 2015). The polylactic
acid mesh is broken down and removed over time (Tamai 2000).
The same types of drugs (everolimus, paclitaxel, sirolimus) used in
drug-eluting stents along with biolimus are used in bioresorbable
stents (Haude 2013; Haude 2016; Puricel 2015).
Bare-metal stents, drug-eluting stents, and bioresorbable stents are
used in modern PCIs, with drug-eluting stents generally being the
first choice (Windecker 2014). Guidelines recommend that acute
coronary syndrome patients receive 12months of antiplatelet ther-
apy (aspirin and a P2Y12 receptor blocker) regardless of whether
PCI is performed (Windecker 2014). The minimum length of
duration for the implant of the bare-metal stents and drug-eluting
stents is recommended to be one month and six months, respec-
tively (Windecker 2014).
Adverse events associated with PCI include death, coronary artery
complications (such as perforation of the artery, distal embolisa-
tion (passage of an intravascular mass, which is capable of clogging
capillaries), or stent thrombosis), myocardial infarction (type four
myocardial infarction) (Thygesen 2012), vascular complications
(such as bleeding or infection at the access site, retroperitoneal
bleeding, or atheroembolism), stroke, and acute kidney failure
(Baim 1996; Cantor 1998; Stankovic 2004).
How the intervention might work
PCI aims to decrease the stenosis of the coronary artery resulting
in increased blood flow to the myocardium of the heart, which
is thought to limit ischaemia and potentially reinfarction. Drug-
eluting stents may be more beneficial than bare-metal stents be-
cause they release antiproliferative drugs, which cause less neoin-
timal growth (Degertekin 2002; Fajadet 2006; Holmes 2004; Lee
2005; Morice 2002; Moses 2003; Stone 2004; Stone 2004a). The
new bioresorbable stents as well as the polymer-free drug-eluting
stents may be even more beneficial since they remove material
that has been associated with adverse events (Abizaid 2010; Chen
2015; Haude 2013; Puricel 2015).
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Why it is important to do this review
The prevalence of ischaemic heart disease is considerable and
causes one third of all deaths in patients over the age of 35 years
(Lloyd-Jones 2010; Nichols 2014; Rosamond 2008). Beneficial
treatments can therefore alleviate a considerable disease burden
and healthcare cost.
Former evidence on drug-eluting stents versus bare-
metal stents for acute coronary syndrome
A2010 Cochrane Review compared drug-eluting stents with bare-
metal stents in participants with both acute coronary syndrome
and stable ischaemic heart disease (Greenhalgh 2010). It found
no significant difference on mortality, incidence of acute myocar-
dial infarction, or thrombosis. However, the review showed indi-
cations of beneficial effects of drug-eluting stents on target lesion
revascularisation, target vessel revascularisation, and a composite
outcome of cardiac events compared with bare-metal stents.
Six non-Cochrane Reviews compared drug-eluting stents with
bare-metal stents in participants with ischaemic heart disease (De
Luca 2012; Kastrati 2007; Roukoz 2009; Stettler 2007; Suh 2011;
Zheng 2014). Three reviews included only STEMI patients (De
Luca 2012; Suh 2011; Zheng 2014). Two of the reviews did not
find any difference in either interventionon all-causemortality and
stent thrombosis, but they had a beneficial effect on target vessel
revascularisation (De Luca 2012; Suh 2011). Suh 2011 observed
improvement of recurrentmyocardial infarctionwith drug-eluting
stents, while De Luca 2012 found no effect. Zheng 2014, which
included four trials, compared the effects of bare-metal stents with
drug-eluting stents in STEMI participants at five-year follow-up.
The review found that there was no difference in the interven-
tions with regard to all-cause mortality and acute myocardial in-
farction, as well as no effect on thrombosis, except for its occur-
rence later than one year after PCI. Three reviews assessed the ef-
fects of drug-eluting stents versus bare-metal stents in participants
with ischaemic heart disease (including STEMI, NSTEMI, un-
stable angina pectoris, and stable angina pectoris) (Kastrati 2007;
Roukoz 2009; Stettler 2007). Of the three reviews, two com-
pared sirolimus stents and paclitaxel stents with bare-metal stents
(Roukoz 2009; Stettler 2007), while one compared only sirolimus
stents with bare-metal stents (Kastrati 2007). All reviews found
no statistically significant difference between drug-eluting stents
comparedwith bare-metal stents onmortality.While Stettler 2007
found a beneficial effect in favour of the drug-eluting stents using
sirolimus on myocardial infarction, they found no effect for drug-
eluting stents using paclitaxel. Kastrati 2007 and Roukoz 2009
found no difference between drug-eluting stents versus bare-metal
stents on myocardial infarction. All three reviews found a bene-
ficial effect favouring drug-eluting stents on target vessel revascu-
larisation (Kastrati 2007; Roukoz 2009; Stettler 2007).
Current guidelines on drug-eluting stents versus bare-
metal stents for acute coronary syndrome
The 2011 American College of Cardiology Foundation/American
Heart Association/Society forCardiovascular Angiography and In-
terventions guideline recommends drug-eluting stents as a useful
alternative to bare-metal stents to prevent restenosis in cases where
there is an increased risk of restenosis, and the patient is likely to
be able to tolerate and comply with prolonged dual antiplatelet
therapy (evidence A for STEMI, evidence C for NSTEMI/unsta-
ble angina pectoris, evidence levels are explained in the Glossary,
Appendix 1) (Levine 2011). The clinical situations associated with
increased risk of restenosis are left main disease, small vessels, in-
stent restenosis, bifurcations, diabetes, long lesions, multiple le-
sions, and saphenous vein grafts (Levine 2011; Levine 2016). The
guideline also states that bare-metal stents should be used in pa-
tients with a high risk of bleeding; inability to comply with one
year of dual antiplatelet therapy; or anticipated invasive or surgical
procedures in the next year, which the 2013 American College
of Cardiology Foundation/American Heart Association Guideline
for the Management of ST-Elevation Myocardial Infarction also
recommends (ACEP 2013; Levine 2011).
The National Institute for Health and Care Excellence (NICE)
has assessed the effects of drug-eluting stents (NICE 2008). NICE
recommends drug-eluting stents in cases where the target artery
for treatment has less than a 3 mm calibre or the lesion is longer
than 15 mm, and the price difference between drug-eluting stents
and bare-metal stents is no more than £300 (GBP).
Problems with major adverse cardiac events (MACE)
as an outcome
In recent years, two major reports have described and analysed
several issues regarding the cardiac composite outcome MACE
(Cutlip 2007; Kip 2008). The main issues regarding MACE con-
cern the variability and lack of consistency in which outcomes
are included in the composite outcome (Cutlip 2007; Kip 2008),
which may lead to misleading conclusions. The main issue with
MACE in this particular review is the problem with using target
vessel revascularisation or target lesion revascularisation as compo-
nents of MACE. There are several reasons that this is problematic.
First, it is important to remember that the decision of whether or
not target vessel revascularisation will be performed is based on
a subjective opinion. Since both treatment providers and partic-
ipants will presumably not be blinded to treatment allocation in
the included trials, target vessel revascularisation and target lesion
revascularisation may introduce bias. Secondly, using a compos-
ite outcome consisting of safety endpoints (death and myocardial
infarction) and outcomes presumed to be a measure of procedu-
ral effectiveness (target vessel revascularisation and target lesion
revascularisation) could lead to erroneous conclusions (Kip 2008).
Therefore, we have decided not to use MACE as a composite out-
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come. Instead, we will use a composite cardiovascular outcome
consisting of cardiovascular mortality and myocardial infarction.
This review is an update of a 2010 Cochrane Review that has now
been divided into a review including acute coronary syndrome
participants and a review including stable ischaemic heart disease
participants (Greenhalgh 2010). The present review will do the
following:
1. take full account of the risk of systematic errors (’bias’),
design errors, and risks of random errors (’play of chance’)
(Higgins 2011; Jakobsen 2014; Keus 2010; Thorlund 2011;
Wetterslev 2008);
2. include trials irrespective of outcome, follow-up duration,
and number of participants;
3. assess outcomes at several time points and take into account
the variability of the follow-up period; and
4. include all types of drug-eluting stents, including polymer-
free stents and bioresorbable stents.
O B J E C T I V E S
To assess the benefits and harms of drug-eluting stents versus bare-
metal stents in participants with acute coronary syndrome.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will search for randomised clinical trials (both individual and
cluster-randomised trials) irrespective of publication type, publi-
cation status, publication date, and language. We will either han-
dle non-English studies internally (i.e. by the authors of this re-
view) or enlist external experts skilled in the given language. We
will report any external source of data extraction in the review.
Types of participants
We will include participants of any age with a diagnosis of acute
coronary syndrome (according to the definition of the trialists).
Types of interventions
We will include any type of drug-eluting stents, including biore-
sorbable stents and polymer-free drug-eluting stents.
We will accept any type of medical therapy as a co-intervention to
percutaneous coronary intervention (PCI).
We will include any type of bare-metal stent as a control interven-
tion.
Types of outcome measures
Primary outcomes
1. All-cause mortality.
2. Serious adverse events defined as any untoward medical
occurrence that resulted in death, was life-threatening, was
persistent, or led to significant disability; prolonged
hospitalisation; or any medical event that had jeopardised the
participant or required intervention to prevent it (ICH-GCP
1997).
3. Major cardiovascular event defined as a composite outcome
consisting of cardiovascular mortality and myocardial infarction.
4. Quality of life measured on any valid scale, such as the
Seattle Angina Questionnaire or 36-Item Short Form Survey
(SF-36) (Ware 1992; Wyrwich 2004).
Secondary outcomes
1. Cardiovascular mortality (defined by the trialists).
2. Myocardial infarction (defined by the trialists).
3. Angina on a continuous scale, such as ’angina stability’ and
’angina frequency’ used in the Seattle Angina Questionnaire
(Wyrwich 2004).
Exploratory outcomes
1. Stent thrombosis.
2. Target vessel revascularisation (defined by the trialists). In
general, target vessel revascularisation is any repeat percutaneous
intervention or surgical bypass of any segment of the target vessel
(Hicks 2010).
We will narratively report adverse events, presenting them in a
table.
We will conduct meta-analyses when possible of all dichotomous
and continuous outcomes at the following two time points:
• outcomes assessed at maximal follow-up (this will be the
time point of primary interest); and
• outcomes assessed at three months or earlier.
Search methods for identification of studies
Electronic searches
Wewill identify trials through systematic searches of the following
bibliographic databases:
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• the Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library;
• MEDLINE Ovid;
• Embase Ovid;
• LILACS (Latin American and Caribbean Health Science
Information Database) (BIREME);
• Science Citation Index Expanded (Thomson Reuters Web
of Science);
• BIOSIS Citation Index (Thomson Reuters Web of Science).
The preliminary search strategy for MEDLINE Ovid will be
adapted for use in the other databases (Appendix 2). TheCochrane
sensitivity-maximising RCT filter, Lefebvre 2011, will be applied
to MEDLINE Ovid, and adaptations of it will be applied to the
other databases, except CENTRAL.
We will also conduct a search of the US National Insti-
tutes of Health Ongoing Trials Register ClinicalTrials.gov (
www.clinicaltrials.gov) and the World Health Organization
International Clinical Trials Registry Platform (ICTRP) (
www.apps.who.int/trialsearch). We will also search Google
Scholar manually for trials not found in the preliminary search
(Lefebvre 2011).
We will search all databases from their inception to the present,
and we will impose no restriction on language of publication.
Searching other resources
We will identify additional trials from the reference lists of review
articles and identified trials.
Data collection and analysis
We will perform the review following the recommendations
of theCochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). We will perform the analyses using Review Man-
ager 5 (RevMan 2014), Stata 14 (Stata 2015), and trial sequential
analysis (CTU 2011).
Selection of studies
Two review authors (JF and EEN) will independently screen titles
and abstracts of all of the potentially eligible trials for inclusion.
We will code all of these studies as ’retrieve’ (eligible or potentially
eligible/unclear) or ’do not retrieve’. If there are any disagreements,
we will ask a third author to arbitrate (JCJ). We will retrieve the
full-text trial reports/publications, and two review authors (JF and
EEN) will independently screen the full texts and identify trials
for inclusion. We will report reasons for exclusion of the ineligible
studies. We will resolve any disagreement through discussion, or if
required, we will consult a third person (JCJ).We will identify and
exclude duplicates and collate multiple reports of the same trial
so that each trial, rather than each report, is the unit of interest
in the review. We will record the selection process in sufficient
detail to complete a PRISMA flow diagram and ’Characteristics
of excluded studies’ tables.
Data extraction and management
We will use a data collection form, which we have piloted on
at least one trial in the review, to collect trial characteristics and
outcome data. Two review authors (JF and EEN) will extract trial
characteristics from included trials. We will extract the following
trial characteristics.
1. Methods: duration of the trial, details of any ’run-in’
period, and date of publication.
2. Participants: number randomised, number analysed,
number lost to follow up/withdrawn, mean age, sex, inclusion
criteria, and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected and time points reported.
5. Notes: trial funding and notable conflicts of interest of the
trial authors.
Two review authors (JF and EEN) will independently extract out-
come data from included studies. We will resolve disagreements
by consensus or by involving a third person (JCJ). One review
author (EEN) will transfer data into the Review Manager 5 file
(RevMan 2014). We will double-check that data are entered cor-
rectly by comparing the data presented in the systematic review
with the study reports. A second review author will spot-check
study characteristics for accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (JF and EEN) will independently assess risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve any disagreements by discussion or by involving
another author (JCJ). We will assess the risk of bias according
to the random sequence generation; allocation sequence conceal-
ment; blinding of participants and personnel; blinding of outcome
assessment; incomplete outcome data; selective outcome report-
ing; and other bias sources. This is done because these components
enable classification of randomised trials with a bias assessment
of low, high, or unclear. Trials at high risk of bias overestimate
benefits and underestimate harms (Gluud 2006; Kjaergard 2001;
Lundh 2012; Moher 1998; Savovi 2012; Savovi 2012a; Schulz
1995; Wood 2008). For additional details on how we will assess
risk of bias, see Appendix 3. We will assess risk of bias on both
trial level and outcome level.
Assessment of bias in conducting the systematic
review
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We will conduct the review according to this published protocol
and report any deviations from it in the ’Differences between pro-
tocol and review’ section of the review.
Measures of treatment effect
Dichotomous outcomes
We will calculate risk ratios (RR) with 95% confidence intervals
(CIs) for dichotomous outcomes.
Continuous outcomes
We will include both end scores and change scores in our analyses.
We will use end scores in the analyses if both are reported. We will
calculate the mean differences (MD) and the standardised mean
differences (SMDs) with 95% CIs for continuous outcomes. We
will use the standardised mean difference when the trials all assess
the same outcome but measure it in a variety of ways, e.g. with
different scales (Higgins 2011).
Dealing with missing data
Wewill contact investigators or study sponsors to obtain any miss-
ing data.
Dichotomous outcomes
Wewill not imputemissing values for any outcomes in our primary
analysis. In two of our sensitivity analyses, we will impute data
(see Sensitivity analysis).
Continuous outcomes
We will not impute missing values for any outcomes in our pri-
mary analysis. In our sensitivity analysis for dichotomous and con-
tinuous outcomes, we will impute data (see Sensitivity analysis).
If studies do not report standard deviations (SD), we will calculate
them using data from the trial if possible.
Assessment of heterogeneity
We will primarily investigate forest plots to visually assess any sign
of heterogeneity. We will secondly assess the presence of statisti-
cal heterogeneity by Chi² test (threshold P < 0.10) and measure
the quantities of heterogeneity by the I² statistic (Higgins 2002;
Higgins 2003). We will follow the recommendations for thresh-
olds in the Cochrane Handbook for Systematic Reviews of Interven-
tions (Higgins 2011):
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity; and
• 75% to 100%: may represent considerable heterogeneity.
We will investigate possible heterogeneity through subgroup anal-
yses. Ultimately, we may decide that we should avoid a meta-anal-
ysis (Higgins 2011).
Assessment of reporting biases
We will assess publication bias and other reporting biases by visual
inspection of funnel plots for primary outcomes if we include at
least 10 trials (Higgins 2011). Using the asymmetry of the funnel
plot, we will assess the risk of bias.
For dichotomous outcomes, we will test asymmetry with the Har-
bord test, Harbord 2006, if τ ² is less than 0.1 and with the Rücker
test, Rücker 2008, if τ ² is more than 0.1.
For continuous outcomes, we will use the regression asymmetry
test (Egger 1997).
Data synthesis
Meta-analysis
We will undertake this systematic review according to the recom-
mendations stated in theCochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011), according to Keus 2010, and ac-
cording to the eight-step assessment suggested by Jakobsen 2014.
We will use the statistical software Review Manager 5, provided
by Cochrane, to meta-analyse data (RevMan 2014).
We will use Stata, Stata 2015, in case of zero-event trials where Re-
view Manager 5’s zero-event handling (replacing zero with a con-
stant of 0.5) is not sufficient, e.g. in cases with a skewed number of
participants between groups, which we will handle with reciprocal
zero-event handling according to Sweeting 2004, and in case we
need to undertake meta-regression (posthoc).
We will use trial sequential analysis (TSA) to assess and control
the risk of random error. If the review does not reach the required
information size, we will present TSA-adjusted confidence inter-
vals to account for the lack of information.
If the included studies report both end scores and change-from-
baseline scores, meta-analysing continuous outcomes, we will use
end scores. If they report only change, we will analyse the results
together with end scores (Higgins 2011a).
We will include all studies in our initial analyses and conduct
a sensitivity analysis of studies at low risk of bias. If the results
are similar, we will base our primary conclusions on the overall
analysis. If they differ, we will base our primary conclusions on
studies at low risk of bias.
Trial sequential analysis
Cumulative meta-analyses are at risk of producing random errors
due to sparse data and multiple testing of accumulating data (Brok
7Drug-eluting stents versus bare-metal stents for acute coronary syndrome (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2008; Brok 2009; Higgins 2011a; Pogue 1997; Thorlund 2009;
Wetterslev 2008); therefore, TSA can be applied to control this
risk (CTU 2011; www.ctu.dk/tsa;Thorlund 2011). The required
information size (that is, the number of participants needed in
a meta-analysis to detect or reject a certain intervention effect)
can be calculated in order to minimise random errors (Wetterslev
2008; Wetterslev 2009). The required information size takes into
account the event proportion in the control group, the assump-
tion of a plausible relative risk reduction, and the heterogeneity
of the meta-analysis (Wetterslev 2008; Wetterslev 2009; Turner
2013). TSA enables testing for significance each time a meta-anal-
ysis includes a new trial. On the basis of the required information
size, trial sequential monitoring boundaries can be constructed.
This enables one to determine the statistical inference concerning
cumulative meta-analysis that has not yet reached the required in-
formation size (Wetterslev 2008).
Firm evidence for benefit or harms may be established if the trial
sequential monitoring boundary is crossed before reaching the re-
quired information size, in which case further trials may turn out
to be superfluous. In contrast, if the boundaries for benefit or harm
are not surpassed, one may conclude that it is necessary to con-
tinue with further trials before a certain intervention effect can be
detected or rejected. Firm evidence for lack of the postulated inter-
vention effect can also be assessed with TSA. This occurs when the
cumulative Z-score crosses the trial sequential monitoring bound-
aries for futility.
To control the risks of random error, we have used relatively con-
servative estimations of the anticipated intervention effect esti-
mates (Jakobsen 2014). Large anticipated intervention effects lead
to small required information sizes, and the thresholds for signifi-
cance will be less strict after the information size has been reached
(Jakobsen 2014).
We will analyse all primary and secondary outcomes with TSA.
We will use the following assumptions.
Primary outcomes
We will estimate the diversity-adjusted required information size
based on the proportion of participants with an outcome in the
control group (Wetterslev 2009). We will use an alpha of 2%
(Jakobsen 2014), a beta of 20%, and the diversity suggested by
the trials in the meta-analysis (Jakobsen 2014).
As anticipated intervention effects for the primary outcomes in
the trial sequential analysis, we will use the following relative risk
reductions or increases because they seem to be the maximum re-
alistic intervention effect estimates based on former studies, trials,
and meta-analyses.
• All-cause mortality: relative risk reduction or increase of
10% (De Luca 2012; Suh 2011).
• Serious adverse events: relative risk reduction or increase of
10%.
• Major cardiovascular event defined as a composite outcome
consisting of cardiovascular mortality and myocardial infarction:
relative risk reduction or increase of 10% (De Luca 2012; Suh
2011).
• Quality of life measured on any valid scale, such as the
Seattle Angina Questionnaire or SF-36: we will use the observed
SD, a clinically relevant mean difference equal to SD/2.
Secondary outcomes
We will estimate the diversity-adjusted required information size
based on the proportion of participants with an outcome in the
control group (Wetterslev 2009). We will use an alpha of 2.5%
(Jakobsen 2014), a beta of 10%, and the diversity suggested by
the trials in the meta-analysis (Jakobsen 2014).
As anticipated intervention effects for the secondary outcomes in
the trial sequential analysis, we will use the following relative risk
reductions or increases because they seem to be realistic interven-
tion effect estimates based on former studies, trials, and meta-
analyses as cited below.
• Angina (continuous outcome): we will use the observed
SD, a clinically relevant mean difference equal to SD/2.
Exploratory outcomes
• Stent thrombosis: relative risk reduction or increase of 10%
(De Luca 2012; Suh 2011).
• Target vessel revascularisation: relative risk reduction or
increase of 30% (De Luca 2012; Suh 2011).
As a supplementary trial sequential analysis, we will use the limit
of the confidence interval closest to zero effect as the anticipated
intervention effect for all trial sequential analyses (Jakobsen 2014).
Assessment of significance
We will assess our intervention effects with both random-effects
meta-analyses, DerSimonian 1986, and fixed-effectmeta-analyses,
Demets 1987, andwewill use themore conservative point estimate
of the two (Jakobsen 2014). The more conservative point estimate
is the estimate closest to zero effect. If the two estimates are equal,
we will use the estimate with the widest confidence interval. We
have four primary outcomes and will therefore consider a P value
less than 2% as significant (Jakobsen 2014). We will use the eight-
step procedure to assess if the thresholds for significance are crossed
or not (Jakobsen 2014).
We will present a table describing the types of serious adverse
events in each trial.
’Summary of findings’ tables
Wewill use the GRADE system to assess the quality of the body of
evidence associated with each of the primary outcomes (all-cause
mortality, serious adverse events, major cardiovascular events, and
quality of life) and secondary outcomes (cardiovascular mortal-
ity, myocardial infarction, and angina) in our review (Guyatt
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2008), constructing ’Summary of findings’ (’SoF’) tables using
the GRADEpro software (www.gradepro.org). The GRADE ap-
proach appraises the quality of a body of evidence based on the
extent to which one can be confident that an estimate of effect or
association reflects the item being assessed. The quality measure
of a body of evidence considers within-study risk of bias, the di-
rectness of the evidence, heterogeneity of the data, precision of ef-
fect estimates, and risk of publication bias (Guyatt 2008). We will
assess the precision of the effect estimates according to Jakobsen
and colleagues (Jakobsen 2014). We will include all studies in our
analyses and conduct a sensitivity analysis with studies at low risk
of bias. If we include no studies at low risk of bias, we will conduct
the sensitivity analysis with studies that have low risk of bias in
all domains other than ’blinding of participants and personnel’. If
the results are similar, we will base our primary ’SoF’ tables and
primary conclusions on the overall analysis. If they differ, we will
base our primary ’SoF’ and primary conclusions on studies with
low risk of bias or alternatively, studies with low risk of bias in all
’Risk of bias’ domains except ’blinding of participants and person-
nel’ (Gluud 2006; Kjaergard 2001; Lundh 2012; Moher 1998;
Savovi 2012; Schulz 1995; Wood 2008).
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses.
A) Type of drug-eluting stents used:
• paclitaxel-eluting stents;
• sirolimus-eluting stents;
• zotarolimus-eluting stents;
• everolimus-eluting stents;
• bioresorbable stents;
• polymer-free drug-eluting stents; and
• mixed drug-eluting stents.
B) Unstable angina pectoris/non-ST-segment elevation myocar-
dial infarction participants compared with ST-segment elevation
myocardial infarction participants.
C) Length of maximum follow up:
• less than or equal to six months;
• between six months and 12 months;
• between one year and three years; and
• more than or equal to three years.
D) Participants with diabetes compared with participants without
diabetes.
E) Participants with high risk of bleeding (as defined by trialists)
compared with participants without high risk of bleeding.
F) Age of participants:
• age 0 to 18;
• age 19 to 75; and
• age 76 or above.
G) Comparison of the effect of drug-eluting stents versus bare-
metal stents between trials with different clinical trial registration
status:
• preregistration;
• postregistration; and
• no registration.
We will only use the primary outcomes in our subgroup analyses.
We will use the formal test for subgroup differences in Review
Manager 5 (RevMan 2014).
Sensitivity analysis
To assess the potential impact of bias, we will perform a sensitivity
analysis where we exclude trials with an overall high risk of bias.
As a secondary sensitivity analysis, we will only include trials with
low risk of bias in all domains except ’blinding of participants and
personnel’, as we do not expect to find any trials at low risk of bias
in this domain. We will thoroughly discuss the limitations of this
sensitivity analysis in the discussion section (Hróbjartsson 2014;
Pocock 2015).
To assess the potential impact of themissing data for dichotomous
outcomes, we will perform the two following analyses.
1. ’Best-worst-case’ scenario: we will assume that all
participants lost to follow up in the experimental group survived,
had no serious adverse event, had no major cardiovascular event,
had no stent thrombosis, and had no target vessel
revascularisation. We will assume that they also had a beneficial
event with regard to quality of life and angina, defined as the
group mean plus both one and two standard deviations of the
group mean (Jakobsen 2014). We will assume that all of those
with missing outcomes in the control group died, had a serious
adverse event/s, had a major cardiovascular event, had stent
thrombosis, and had target vessel revascularisation. We will
assume that they also had a harmful event with regard to quality
of life and angina, defined as the group mean plus both one and
two standard deviations of the group mean (Jakobsen 2014).
2. ’Worst-best-case’ scenario: we will assume that all
participants lost to follow up in the experimental group died,
had a serious adverse event, had a major cardiovascular event,
had stent thrombosis, and had target vessel revascularisation. We
will assume that they also had a harmful event with regard to
quality of life and angina, defined as the group mean plus both
one and two standard deviations of the group mean (Jakobsen
2014). We will assume that all of those with missing outcomes in
the control group survived, had no serious adverse event, had no
major cardiovascular event, had no stent thrombosis, and had no
target vessel revascularisation. We will assume that they also had
a beneficial event with regard to quality of life and angina,
defined as the group mean plus both one and two standard
deviations of the group mean (Jakobsen 2014).
We will present results from both scenarios.
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To assess the potential impact of missing SDs for continuous out-
comes, we will perform the following sensitivity analyses.
• Where SDs are missing and not possible to calculate, we
will impute SDs from trials with similar populations and low risk
of bias.
• If we find no such trials, we will impute SDs from trials
with a similar population. As the final option, we will impute
SDs from all trials.
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A P P E N D I C E S
Appendix 1. Glossary
Ischaemic: reduced blood supply to an organ.
ST: ST is short for the ST-segment, which is a specific segment of the printout when recording an electrocardiogram. It is used to
differentiate between ST and non-ST myocardial infarction.
Angina pectoris: medical term for chest pain or discomfort due to ischaemic heart disease.
Myocardial ischaemia: reduced blood supply to the heart.
Cardiomyocyte necrosis: undesirable death of the cells of the heart.
Non-ST-elevation myocardial infarction: a kind of heart attack which does not show ST-segment elevation on an electrocardiogram.
ST-elevation myocardial infarction: a kind of heart attack which shows ST-segment elevation on an electrocardiogram.
Troponin I: a cardiac protein which is released during a heart attack
Troponin T: a cardiac protein which is released during a heart attack
Myocardial band isoenzyme of creatine kinase (CK-MB): a specific type of the enzyme creatine kinase, which is highly specific for the
heart.
Atherosclerosis: arterial wall-thickening due to build up of plaque.
Intraluminal thrombus: formation of a clot inside a vessel.
Arrhythmias: deviation from the normal heart rhythm.
Hypertension: increased pressure typically inside the arteries.
Hypotension: decreased pressure typically inside the arteries.
Percutaneous: through the skin.
Stent thrombosis: blockage of the stent by a blood clot.
Angiography: visualisation of the blood vessels typically by injection of contrast and using x-ray.
Ventricular arrhythmias: deviation from the normal heart rhythm involving the ventricles of the heart.
Myocyte: a heart muscle cell.
Continuous ischaemia: prolonged reduced blood supply (to the heart).
Myocardium: the muscle tissue of the heart.
Myocardial necrosis: death of the muscle tissue of the heart.
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Acute decompensated heart failure: heart failure where the heart is unable to overcome the pressure in the blood vessels and results in
symptoms such as difficulty breathing, edema, and fatigue.
Systolic: the time period in which the ventricles of the heart contract.
Diastolic: the time period in which the ventricles of the heart relax.
Nonocclusive thrombus: the blood clot does not completely prevent blood flow through the vessel.
Coronary vasoconstriction: narrowing due to muscle contraction of the blood vessels of the heart.
Restenosis: narrowing of a previously narrowed blood vessel due to a blood clot.
Thyrotoxicosis: excessive levels of the hormone produced by the thyroid gland resulting in unwanted symptoms.
Tachycardia: a faster than normal heart beat typically above 100 beats per minute.
Biolimus: the trade name of the drug Umirolimus. The mechanism of action is believed to be anti proliferation of smooth muscle cells.
Atheroembolism: embolism originating from an atherosclerotic plaque.
Retroperitoneal bleeding: bleeding behind the peritoneum, a membrane lining the abdominal cavity.
Stenosis: narrowing of a vessel.
Neointimal: scar tissue formed in a vessel after an injury.
Revascularisation: removing the cause of the stenosed blood vessel, allowing blood flow to resume.
Sirolimus stent: a stent using the sirolimus drug, a drug used in stents with the aim of reducing restenosis.
Paclitaxcel stent: a stent using the paclitaxel drug, a drug used in stents with the aim of reducing restenosis.
Bifurcation: when a blood vessel splits into two different blood vessels.
Saphenous vein grafts: when performing bypass surgery, one may use the saphenous vein (located in the leg) to bypass the occluded
vessel, ultimately reestablishing heart flow.
Bioresorbable stents: stents that are absorbed after initial placement with the intent of reducing restenosis.
Percutaneous coronary intervention: an intervention where a balloon is guided up to the heart through an access sheath penetrating
the skin to reduce a narrowing of a blood vessel.
Balloon angioplasty: using a balloon to open a narrowed vessel.
Re-endothelialisation: regrowth of endothelium after injury.
Everolimus: a drug used in stents with the aim of reducing restenosis.
Zotarolimus: a drug used in stents with the aim of reducing restenosis
Paclitaxel: a drug used in stents with the aim of reducing restenosis
Sirolimus: a drug used in stents with the aim of reducing restenosis
Level of evidence A: data derived from multiple randomized clinical trials or meta-analyses.
Level of evidence B: data derived from a single randomized clinical trial or large non-randomized studies.
Level of evidence C: consensus of opinion of the experts and/ or small studies, retrospective studies, registries.
Appendix 2. Preliminary MEDLINE Ovid search strategy
1. Stents/
2. stent*.tw.
3. 1 or 2
4. drug elut*.tw.
5. Sirolimus/
6. sirolimus.tw.
7. rapamycin.tw.
8. paclitaxel.tw.
9. taxol.tw.
10. exp Immunosuppressive Agents/
11. coat* stent*.tw.
12. exp Taxoids/
13. taxane*.tw.
14. qp2.tw.
15. hexanoyltaxol.tw.
16. everolimus.tw.
17. abt-578.tw.
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18. Tacrolimus/
19. Dactinomycin/
20. actinomycin.tw.
21. batimastat.tw.
22. exp Dexamethasone/
23. dexamethasone.tw.
24. exp Estradiol/
25. estradiol.tw.
26. praxel.tw.
27. paxene.tw.
28. onxol.tw.
29. anzatax.tw.
30. immunosuppress*.tw.
31. prograf*.tw.
32. meractinomycin.tw.
33. cosmegen.tw.
34. dactinomycin.tw.
35. millicorten.tw.
36. maxidex.tw.
37. decaspray.tw
38. dexpak.tw.
39. dexasone.tw.
40. oradexon.tw.
41. hexadecadrol.tw.
42. decaject.tw.
43. hexadrol.tw.
44. decameth.tw.
45. methylfluorprednisolone.tw.
46. vivelle.tw.
47. oestradiol.tw.
48. estrace.tw.
49. aerodiol.tw.
50. estraderm.tw.
51. ovocyclin.tw.
52. estramustin*.tw.
53. estracyt.tw.
54. emcyt.tw.
55. tacrolimus.tw.
56. taxoids.tw.
57. zotarolimus.tw.
58. umirolimus.tw.
59. biolimus.tw.
60. pimecrolimus.tw.
61. elidel.tw.
62. or/4-61
63. 3 and 62
64. eluting stent*.tw.
65. 63 or 64
66. exp Angioplasty, Balloon, Coronary/ or exp Percutaneous Coronary Intervention/
67. balloon angioplast*.tw.
68. (percutaneous adj6 coronary intervention*).tw.
69. PCI.tw.
70. (intervention* adj6 percutaneous coronary).tw.
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71. (revascularization* adj6 percutaneous coronary).tw.
72. (angioplast* adj6 coronary).tw.
73. percutaneous coronary.tw.
74. ((transluminal or trans-luminal) adj6 coronary).tw.
75. or/66-74
76. exp Myocardial Ischemia/
77. ((myocardial or myocardium or subendocardial or transmural or cardiac or cardial or coronary or heart) adj2 (infarct* or postinfarct*
or hypoxi* or anoxi* or failure* or decompensation or insufficien*)).tw.
78. (heart disease* or coronary disease* or IHD or CIHD or CHD).tw.
79. (myocardial dysfunction or angina or stenocardia).tw.
80. ((ischemi* or ischaemi*) adj2 (myocardium or myocardial or heart or coronary or cardiac or cardial or subendocardial or cardiomy-
opath*)).tw.
81. ((artery occlusion* or artery disease* or arterioscleros* or atheroscleros*) adj2 coronary).tw.
82. or/76-81
83. Acute Coronary Syndrome/
84. exp Myocardial Infarction/
85. exp Coronary Thrombosis/
86. coronary thrombosis.tw.
87. acute coronary.tw.
88. exp Angina, Unstable/
89. myocardial infarct*. tw.
90. heart infarct*.tw.
91. acs.tw.
92. ami.tw.
93. (coronary adj3 syndrome*).tw.
94. acute angina.tw.
95. (unstable adj3 angina).tw.
96. unstable coronary.tw.
97. or/83-96
98. randomized controlled trial.pt.
99. controlled clinical trial.pt.
100. randomized.ab.
101. placebo.ab.
102. drug therapy.fs.
103. randomly.ab.
104. trial.ab.
105. groups.ab.
106. or/98-105
107. exp animals/ not humans.sh.
108. 106 not 107
109. 65 or 75
110. 82 or 97
111. 108 and 109 and 110
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Appendix 3. Details on assessment of risk of bias
We will classify each trial according to the domains below for each outcome result.
Random sequence generation
• Low risk: if sequence generation is achieved using a computer random number generator or a random numbers table. We will
also consider drawing lots, tossing a coin, shuffling cards, and throwing dice as adequate if an independent adjudicator performs these
methods.
• Unclear risk: if there is insufficient information to permit judgement of ’low risk’ or ’high risk’.
• High risk: if the allocation sequence is not randomised or only quasi-randomised.
Allocation sequence concealment
• Low risk: if the allocation of participants results from a central independent unit, on-site locked computer, identical-looking
numbered sealed opaque envelopes, drug bottles or containers prepared by an independent investigator.
• Unclear risk: if there is insufficient information to permit judgement of ’low risk’ or ’high risk’.
• High risk: if the allocation sequence is known to the investigators who assigned participants.
Blinding of participants and personnel
• Low risk: if the participants and the personnel are blinded to treatment allocation and this is described.
• Unclear risk: if there is insufficient information to permit judgement of ’low risk’ or ’high risk’.
• High risk: if blinding of participants and personnel is not performed.
Blinding of outcome assessment
• Low risk: if the trial investigators performing the outcome assessments, analyses, and calculations are blinded to the intervention.
• Unclear risk: if there is insufficient information to permit judgement of ’low risk’ or ’high risk’.
• High risk: if blinding of outcome assessment is not performed.
Incomplete outcome data
• Low risk: (1) there are no dropouts or withdrawals for all outcomes, or (2) the numbers and reasons for the withdrawals and
dropouts for all outcomes are clearly stated, can be described as being similar in both groups, and the trial handles missing data
appropriately in intention-to-treat analysis using proper methodology, e.g. multiple imputations*. As a general rule, we will judge the
trial as at low risk of bias due to incomplete outcome data if the number of dropouts is less than five per cent. However, the five per
cent cut off is not definitive.
• Unclear risk: if there is insufficient information to permit judgement of ’low risk’ or ’high risk’.
• High risk: the pattern of dropouts can be described as being different in the two intervention groups or the trial uses improper
methodology in dealing with the missing data, e.g. last observation carried forward.
*Multiple imputation is a general approach to the problem of missing data. It aims to allow for the uncertainty about the missing data
by creating several different plausible imputed data sets and appropriately combining results obtained from each of them. The first stage
is to create multiple copies of the dataset, with the missing values replaced by imputed values. These are sampled from their predictive
distribution based on the observed data; thus, multiple imputation is based on a bayesian approach. The imputation procedure must
fully account for all uncertainty in predicting the missing values by injecting appropriate variability into the multiple imputed values.
The second stage is to use standard statistical methods to fit the model of interest to each of the imputed datasets. The estimated
associations from the imputed datasets will differ and are only useful when averaged together to give overall estimated associations.
Valid inferences are obtained because we are averaging over the distribution of the missing data given the observed data (Sterne 2009).
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Selective outcome reporting
• Low risk: a protocol is published before or at the time the trial begins and the outcomes called for in the protocol are reported
on. If there is no protocol or the protocol is published after the trial begins, reporting of the primary outcomes will grant the trial a
grade of low risk of bias.
• Unclear risk: if there is no protocol and the primary outcomes are not reported on.
• High risk: if the outcomes that are called on in a protocol are not reported on.
Other bias risk
• Low risk of bias: the trial appears to be free of other components (for example, academic bias or for-profit bias) that could put it
at risk of bias.
• Unclear risk of bias: the trial may or may not be free of other components that could put it at risk of bias.
• High risk of bias: there are other factors in the trial that could put it at risk of bias (for example, authors have conducted trials on
the same topic, for-profit bias, etc).
Overall risk of bias
• Low risk of bias: we will classify the outcome result as overall ’low’ risk of bias only if we classify all of the bias domains described
in the aforementioned text as low risk of bias. Due to the nature of the PCI procedure, we do not expect to find any trials at low risk
of bias. We provide a description of how we will deal with this scenario in Data synthesis.
• High risk of bias: we will classify the outcome result as ’high’ risk of bias if we classify any of the bias risk domains in the
aforementioned text as ’unclear’ or ’high’ risk of bias.
We will grade each potential source of bias as high, low, or unclear and provide a quote from the study report together with a justification
for our judgment in the ’Risk of bias’ table. We will summarise the ’Risk of bias’ judgements across different studies for each of the
domains listed. Where information on risk of bias relates to unpublished data or correspondence with a trialist, we will note this in the
’Risk of bias’ table.
When considering treatment effects, we will take into account the risk of bias for the studies that contribute to that outcome.
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